Navigation Links
Inovio Pharmaceuticals' Prostate Cancer DNA Vaccine Demonstrates Strong T Cell Responses in Monkeys; Company on Track for Phase I Clinical Trial
Date:6/29/2011

ts from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company's technology by potential corporate or other partners or collaborators, capital market conditions, our ability to successfully integrate Inovio and VGX Pharmaceuticals, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2010, our Form 10-Q for the three months ended March 31, 2011, and other regulatory filings from time to time. There can be no assurance that any product in Inovio's pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that an
'/>"/>

SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Inovio Pharmaceuticals to Present at 13th Annual BIO CEO & Investor Conference
2. Inovio Pharmaceuticals Foot-and-Mouth Disease DNA Vaccine Introduces Critical Advantages in Fight Against Most Serious Farm Animal Disease
3. Inovio Pharmaceuticals Enters Phase II Clinical Trial with SynCon™ DNA Vaccine for Cervical Dysplasia Caused by HPV
4. Inovio Pharmaceuticals Reports Long-Term Immune Responses from Therapeutic Cervical Dysplasia and Cancer DNA Vaccine
5. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
6. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
7. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
8. ADVENTRX Pharmaceuticals to Report Second Quarter 2008 Results
9. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
10. VIA Pharmaceuticals to Present at Fourth Annual Noble Financial Equity Conference
11. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... , Dec. 15, 2014  GlassesOff Inc. (OTCBB: GLSO) ... as an independent director of the Company,s Board ... AeroScout and served as its CEO until its acquisition ... a $240 million transaction. Recognized as the inventor of ... leadership, AeroScout provided Wi-Fi -based RFID solutions focused on ...
(Date:12/15/2014)... , Dec. 15, 2014  Ascendis Pharma A/S, ... technology to address significant unmet medical needs, today ... Phase 2 pediatric study to evaluate once-weekly TransCon ... or GHD.  This interim analysis consists of 25 ... enrollment in the study, completing all six months ...
(Date:12/13/2014)... and Virgin Unite Canada, the non-profit foundation of the Virgin ... Canadian entrepreneurs tackling social and environmental challenges. Today, Sir ... Centre to announce the new partnership, which includes the development ... $1 million in seed capital provided by Virgin Unite Canada ... Foundation, founded by Alison Lawton . ...
(Date:12/13/2014)... The DNA Microarray market market was valued at ... grow at a CAGR of 15.2% from 2014 ... the DNA Microarray for an in-depth analysis of ... various tables and figures. , http://www.micromarketmonitor.com/market-report/dna-microarray-reports-5177428198.html ... instrument, consumables, and services, where the consumables market ...
Breaking Biology Technology:AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4MaRS and Virgin Unite partner to invest in business as a force for good 2MaRS and Virgin Unite partner to invest in business as a force for good 3DNA Microarray Market Is Expected to Grow at a CAGR of 15.2% from 2014 to 2019 - A Report by MicroMarket Monitor 2DNA Microarray Market Is Expected to Grow at a CAGR of 15.2% from 2014 to 2019 - A Report by MicroMarket Monitor 3DNA Microarray Market Is Expected to Grow at a CAGR of 15.2% from 2014 to 2019 - A Report by MicroMarket Monitor 4
... - No Incidences of Nonconformance Found for Last ... ... ... Sept. 6 Carrington,Laboratories, Inc. (Pink Sheets: CARN) today announced that its bulk,pharmaceutical manufacturing ...
... Generic Industry Readiness and Questions Fiscal ... of Delaying Biogenerics -, WASHINGTON, Sept. 6 ... decades-old patents,expire, and generic companies stand ready to add ... pass legislation enabling the U.S.,Food and Drug Administration (FDA) ...
... Boston Scientific,Corporation (NYSE: BSX ) today announced that ... a Director. Mr. Elliott, 58, is Chairman of ... Chairman, President and Chief Executive Officer of,Zimmer from 2001 ... Elliott,has extensive operating and director experience in medical devices,orthopaedics ...
Cached Biology Technology:Carrington Reports on ISO 9001:2000 Inspection at Sabila Industrial in Costa Rica 2Carrington Reports on ISO 9001:2000 Inspection at Sabila Industrial in Costa Rica 3Biogenerics Will Save Billions, Says Hospira CEO 2Biogenerics Will Save Billions, Says Hospira CEO 3Biogenerics Will Save Billions, Says Hospira CEO 4Boston Scientific Announces Election of Ray Elliott to Its Board of Directors 2Boston Scientific Announces Election of Ray Elliott to Its Board of Directors 3
(Date:12/17/2014)... DUBLIN , Dec. 15, 2014 Research ... announced the addition of the "Samsung Galaxy ... Analysis" report to their offering. ... on a totally different sensing technology than the ... a fingerprint sensor in its product. ...
(Date:12/17/2014)... Dec. 16, 2014 Research and Markets ... of the "Global Chemical Sensor Market 2015-2019" ... http://photos.prnewswire.com/prnh/20130307/600769 One major ... demand for medical sensors in biomedical applications. Chemical ... quick and correct diagnosis during surgical procedures. The ...
(Date:12/11/2014)... 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition ... report to their offering. ... the adoption of multimodal biometric systems. Multimodal biometric ... individual for verification and identification purposes. This helps ...
Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... Children,s National Medical Center have discovered that ... are significantly more likely to have low levels of ... This study supports recent research that suggests vitamin D ... keeping bones healthy. Vitamin D deficiency has been recently ...
... March 17 Orbel,s innovative Board Shield ... PCB shield. Visit the BLS section   ... variety of surface mount or through-hole configurations. Then click ... lets you enter shield dimensions, mounting style, and ...
... In the 1930s, soil used as ballast to weigh down ... red imported fire ant to the southern United States. Since ... Maryland and as far west as California, shorting out streetlights ... Plant pests like the fire ant cost the U.S. ...
Cached Biology News:Study: Low levels of vitamin D linked to higher rates of asthma in African-American kids 2Orbel Introduces the Board Shielding Wizard 2From international harbor to native habitat 2From international harbor to native habitat 3
... used as a fusion partner when expressing ... sequence has been reported to enhance the ... of its fusion partners. When expressed in ... proteins can be purified with immobilized glutathione. ...
... The potential applications for the use of ... gene expression via the RNA interference (RNAi) ... cellular and molecular biology fields. siRNA for ... either chemically or enzymatically, and then transfected ...
... The 820-MS features Varians unique collision ... simple, routine removal of troublesome spectroscopic ... flexible interference-free analysis without the worry ... ion guides, or cells. And, by ...
Acetylcholinesterase (human brain, AChE)...
Biology Products: